Login to Your Account



FDA Rebuffs Pharmacyclics' Xcytrin In NSCLC Yet Again

By Donna Young


Thursday, December 27, 2007
The FDA told Pharmacyclics Inc. that Xcytrin (motexafin gadolinium) injection in combination with radiation was not approvable to treat patients with non-small-cell lung cancer (NSCLC) whose disease has spread to the brain. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription